evidence table
Alpha Lipoic Acid Blood Glucose Meta-Analysis Evidence Table
Structured evidence table for Alpha Lipoic Acid Blood Glucose Meta-Analysis, generated from 2 reusable source documents in the Migaku knowledge base.
| topic | claim | evidence level | citation | source |
|---|---|---|---|---|
| Alpha Lipoic Acid Blood Glucose Meta-Analysis | ALA reduced LPS-induced interleukin-1β (IL-1β) secretion in a concentration-dependent manner, whereas a modest but significant decrease in tumor necrosis factor-alpha (TNF-α) was observed only at the highest dose (2000 μM; p p p < 0.05). | 4 | Ko CY (2026) | Alpha-Lipoic Acid Reduces NLRP3/ASC Expression and IL-1β Release in Kupffer Cells and Improves Insulin Signaling in FL83B Hepatocytes Exposed to a Conditioned Medium. |
| Alpha Lipoic Acid Blood Glucose Meta-Analysis | Type 2 diabetes mellitus (T2DM) is characterized by insulin resistance and chronic inflammation. | 4 | Ko CY (2026) | Alpha-Lipoic Acid Reduces NLRP3/ASC Expression and IL-1β Release in Kupffer Cells and Improves Insulin Signaling in FL83B Hepatocytes Exposed to a Conditioned Medium. |
| Alpha Lipoic Acid Blood Glucose Meta-Analysis | This study investigated whether alpha-lipoic acid (ALA), a redox-active compound with established anti-inflammatory properties, can inhibit the activation of the nucleotide-binding oligomerization domain-like receptor family pyrin domain-containing 3 (NLRP3) inflammasome in lipopolysaccharide (LPS)-stimulated Kupffer cells and mitigate inflammation-induced insulin resistance in FL83B hepatocytes. | 4 | Ko CY (2026) | Alpha-Lipoic Acid Reduces NLRP3/ASC Expression and IL-1β Release in Kupffer Cells and Improves Insulin Signaling in FL83B Hepatocytes Exposed to a Conditioned Medium. |
| Alpha Lipoic Acid Blood Glucose Meta-Analysis | During the study period, 3 patients in the roflumilast group dropped out secondary to non-adherence (n=2) and the development of thyroid cancer (n=1), and 3 patients in the alpha-lipoic acid group also dropped out as a result of non-compliance. | 4 | Elsharab Asmaa (2025) | Efficacy and Safety of Roflumilast versus Alpha-Lipoic Acid in Type 2 Diabetes with Neuropathy: A Comparative Clinical Study |
| Alpha Lipoic Acid Blood Glucose Meta-Analysis | Roflumilast treatment reduced FBG from 140 (17) to 118 (11) (P1<0.001), while alpha-lipoic acid reduced FBG from 139 (12) to 123 (10) (P1<0.001). | 4 | Elsharab Asmaa (2025) | Efficacy and Safety of Roflumilast versus Alpha-Lipoic Acid in Type 2 Diabetes with Neuropathy: A Comparative Clinical Study |
| Alpha Lipoic Acid Blood Glucose Meta-Analysis | Roflumilast decreased HOMA-IR from 4.33 (0.646) to 2.69 (0.889) (P1<0.001), whereas alpha-lipoic acid reduced it from 4.29 (0.529) to 3.28 (0.526) (P1 < 0.001). | 4 | Elsharab Asmaa (2025) | Efficacy and Safety of Roflumilast versus Alpha-Lipoic Acid in Type 2 Diabetes with Neuropathy: A Comparative Clinical Study |
| Alpha Lipoic Acid Blood Glucose Meta-Analysis | 5 6 7 8 Oxidative stress and inflammation play a central role in the pathogenesis of DN. | 4 | Elsharab Asmaa (2025) | Efficacy and Safety of Roflumilast versus Alpha-Lipoic Acid in Type 2 Diabetes with Neuropathy: A Comparative Clinical Study |
Source documents